louisiana semaglutide gastroparesis lawsuit kentucky nausea attorney digestive blockage law office in gastric intestinal obstruction firm glp-1 louisiana semaglutide gastroparesis law office

WorldatWork & IFEBP, 2024) The Data Explained: GLP-1 Coverage Adoption Coverage for GLP-1s among large employers (500+ employees) grew from 41% in 2023 to 44% in 2024, with projections showing continued expansion as employers weigh cost versus employee demand (Intercept Health, HR Dive)

The goal is consistency and comfort, not variety or perfection

Understanding what GLP-1 is, along with rising GLP-1 demand, helps employers make informed coverage decisions

It reinforces why researchers continue comparing CagriSema vs retatrutide closely

Current evidence suggests that GLP-1 receptor agonists are not only safe for patients with fatty liver disease but may offer specific hepatic benefits beyond weight loss alone